Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Canton Strategic Holdings, Inc. filings document the completed name change from Tharimmune, Inc. and ticker change from THAR to CNTN, along with the company's digital asset treasury strategy tied to Canton Coin and the Canton Network. The 8-K record covers material events, amended charter and bylaws, Regulation FD disclosures, full-year operating and financial results, and governance participation through the Canton Foundation.
Its filings also describe capital-structure matters, including registered offerings, at-the-market sales agreements, Form S-3 registration statements, common stock and pre-funded warrant issuance, and related material agreements. Governance disclosures address board composition, bylaws, shareholder matters, and the company's public reporting profile across digital asset treasury and clinical-stage research activities.
Tharimmune, Inc. appointed Jacob Asbury, 52, as its new Chief Financial Officer effective December 10, 2025, replacing interim CFO Sireesh Appajosyula, who will continue as Chief Executive Officer of subsidiary Gravitas Life Sciences, Inc. The company states there are no special arrangements, family relationships, or related-party transactions tied to Asbury’s appointment.
Under his employment agreement, Asbury will receive a $300,000 annual base salary and will be eligible for a cash-based performance bonus with a $100,000 target, plus potential equity awards at the Board’s discretion. His employment is at will. If he resigns for “good reason” or is terminated without “cause,” he is entitled to accrued pay and benefits plus 12 months of base salary, subject to a release of claims and other standard restrictive covenants.
Tharimmune, Inc. supplements its prospectus for a common stock sales program covering up to $64,910,161 of common stock under a Sales Agreement with Clear Street LLC and President Street Global, LLC.
The supplement discloses that President Street has given notice to terminate its role as a sales agent and that Tharimmune agreed to pay President Street an advisory fee of $1,000,000, in two $500,000 installments tied to the first sales notice and to aggregate sales of $50,000,000 of shares under the Sales Agreement. The company notes its common stock trades on the Nasdaq Capital Market under the symbol THAR, with a last reported sale price of $2.50 per share on December 4, 2025, and reminds investors to review the risk factors in its prospectus and recent SEC reports.
Tharimmune (THAR) filed a Form 3 for Chief Executive Officer Mark Wendland. The filing reports that no securities are beneficially owned by the reporting person. The date of the event requiring the statement is 11/06/2025, and the form was filed by one reporting person.
Tharimmune, Inc. (THAR) filed a Form 3 initial statement of beneficial ownership. The reporting person is an officer serving as President, and the filing indicates no securities are beneficially owned as of the event date 11/06/2025.
This is a routine insider disclosure filed by one reporting person and does not reflect any purchases, sales, or holdings. The signature line is by Mark Toomey.
Tharimmune, Inc. appointed Sireesh Appajosyula as interim Chief Financial Officer. The Board made the appointment on November 7, 2025, with the interim term set not to extend beyond December 31, 2025. The company stated that Mr. Appajosyula’s previously disclosed employment agreement with Tharimmune remains in effect. This is a leadership continuity move while the company finalizes its longer‑term finance leadership plans.
Tharimmune, Inc. entered an at-the-market Sales Agreement to sell shares of common stock with an aggregate offering price of up to $64,910,161 under its existing Form S-3 shelf. Clear Street LLC and President Street Global LLC will act as sales agents.
The company filed a prospectus supplement on November 6, 2025. Sales may occur from time to time via at-the-market transactions, negotiated deals, or block trades, and neither party is obligated to sell; the program can be suspended or terminated upon notice. The agents will receive commissions of up to 3.00% of aggregate gross proceeds, and Tharimmune agreed to reimburse up to $75,000 of certain legal expenses, plus ongoing legal costs. The company also announced, via press release, the closing of a private placement.
Tharimmune, Inc. filed a prospectus supplement to launch an at‑the‑market program to sell up to $64,910,161 of common stock through Clear Street LLC and President Street Global. The Sales Agents will use commercially reasonable efforts and may execute negotiated or Rule 415(a)(4) “at the market offerings,” with compensation of up to 3.0% of gross proceeds.
The company plans to use net proceeds primarily to acquire, hold and stake Canton Coin, operate validators on the Canton Network, and for working capital and general corporate purposes, including potential acquisitions or investments. Tharimmune’s common stock trades on Nasdaq as THAR; the last reported price was $3.99 on November 5, 2025. Shares outstanding were 34,933,919 as of November 6, 2025.
The filing follows a recently closed private placement that issued pre‑funded warrants and generated approximately $545 million in gross proceeds, with most of those proceeds allocated to a digital asset treasury strategy centered on Canton Coin.
Tharimmune, Inc. closed private placements of common stock and pre-funded warrants, issuing 25,966,048 shares and 151,456,115 pre-funded warrants at $3.075 per share (pre-funded at $3.075 less $0.0001), raising approximately $545 million in gross proceeds.
The company plans to use proceeds to establish its Canton Coin treasury and fund operations. Purchasers agreed to lock-ups until a resale registration statement is declared effective. Tharimmune will also issue Strategic Advisor Warrants equal to 5.00% of fully diluted common stock at a $0.001 exercise price.
Leadership changes accompanied the financing: Mark Wendland was appointed Chief Executive Officer and director, and Mark Toomey became President. Two directors, Nancy Davis and Sanam Parikh, resigned, stating no disagreements. Former CEO Sireesh Appajosyula will lead subsidiary Gravitas Life Sciences. Employment agreements include base salaries of $500,000 and defined bonus/severance terms, plus potential RSU grants of 1.0% (Wendland) and 0.9% (Toomey) following the PIPE closing.
Tharimmune (THAR) reported an insider equity award. A director and COO received a stock option grant for 5,000 derivative securities on 11/03/2025 with an exercise price of $3.075 per share. The option is first exercisable on 11/03/2025 and expires on 11/03/2035.
Following the reported transaction, the insider beneficially owned 55,000 derivative securities. The filing lists the ownership form as direct and records the transaction code as an acquisition.
Tharimmune, Inc. (THAR) reported insider activity on a Form 4. Director James Liddy received a stock option grant for 5,000 derivative securities on 11/03/2025 at an exercise price of $3.075 per share. The options are exercisable on 11/03/2025 and expire on 11/03/2035, covering underlying Common Stock (5,000 shares). Following this transaction, Liddy beneficially owns 55,000 derivative securities. The ownership form is reported as Direct (D).